All In Biotech

Investigational drug · Phase 2

AZD0754

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Prostate Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "AZD0754"

First trial start

2024

Mar 12, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AZD0754", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Prostate Cancer

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "AZD0754" as an intervention, largest first.

All trials
  • AstraZenecaAstraZeneca (AZN)

    NCT06194461 · 64 participants (planned) · Start Sep 17, 2025 · Primary completion Nov 29, 2041

    Drug: AZD5851; AZD0754 · For: Hepatocellular Carcinoma; Prostate Cancer

    Sites: Phoenix, Arizona; Duarte, California; Orange, California · 25 sites in all

  • AstraZenecaAstraZeneca (AZN)

    NCT06267729 · 60 participants (planned) · Start Mar 12, 2024 · Primary completion Nov 24, 2026

    Drug: AZD0754; AZD2287 · For: Metastatic Prostate Cancer

    Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 15 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Metastatic Prostate Cancer

  • PalacaparibAZD9574Phase 25 trials

    AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials

    Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer

  • BalstilimabAGEN2034Phase 23 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • AZD2287Imaging agentPhase 22 trials

    AstraZeneca · Metastatic Prostate Cancer

  • ZalifrelimabPhase 22 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • AZD0516Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • AZD8359Phase 21 trial

    AstraZeneca · Metastatic Prostate Cancer

  • GDC-1261Phase 21 trial

    Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.